InsiderTrades.com logo

EDSA Insider Trading

Insider Ownership Percentage: 22.60%
Insider Buying (Last 12 Months): $184,142.18
Insider Selling (Last 12 Months): $0.00

Edesa Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Edesa Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edesa Biotech Share Price & Price History

Current Price: $5.33
Price Change: ▼ Price Decrease of -0.49 (-8.42%)
As of 03/30/2026 05:00 PM ET

This chart shows the closing price history over time for EDSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Edesa Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/10/2026Pardeep NijhawanCEOBuy1,000$6.60$6,600.00628,813View SEC Filing Icon  
3/5/2026Pardeep NijhawanCEOBuy10,000$3.90$39,000.00402,702View SEC Filing Icon  
3/3/2026Pardeep NijhawanCEOBuy10,000$3.63$36,300.00392,702View SEC Filing Icon  
2/27/2026Pardeep NijhawanCEOBuy30,000$2.22$66,600.00371,702View SEC Filing Icon  
2/26/2026Michael J. BrooksPresidentBuy2,000$1.57$3,140.00226,870View SEC Filing Icon  
2/26/2026Pardeep NijhawanCEOBuy20,571$1.58$32,502.18615,797View SEC Filing Icon  
3/25/2024Pardeep NijhawanCEOBuy5,000$4.00$20,000.00341,702View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Edesa Biotech (NASDAQ:EDSA)

5.50% of Edesa Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EDSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Edesa Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2026Diadema Partners LP54,025$77K0.0%N/A0.649%Search for SEC Filing on Google Icon
2/13/2026State Street Corp18,679$27K0.0%N/A0.224%Search for SEC Filing on Google Icon
2/12/2026DRW Securities LLC134,222$0.19M0.0%N/A1.611%Search for SEC Filing on Google Icon
11/17/2025Susquehanna International Group LLP14,610$36K0.0%N/A0.208%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC14,032$34K0.0%-40.3%0.199%Search for SEC Filing on Google Icon
5/15/2025Nantahala Capital Management LLC625,000$1.53M0.1%N/A8.899%Search for SEC Filing on Google Icon
5/15/2025Velan Capital Investment Management LP687,500$1.68M1.7%N/A9.789%Search for SEC Filing on Google Icon
5/14/2025Stonepine Capital Management LLC687,500$1.68M1.6%N/A9.789%Search for SEC Filing on Google Icon
2/17/2025Citadel Advisors LLC40,944$70K0.0%N/A1.180%Search for SEC Filing on Google Icon
2/14/2025Two Sigma Securities LLC15,313$26K0.0%N/A0.441%Search for SEC Filing on Google Icon
8/2/2024CM Management LLC90,000$0.39M0.3%+45.2%2.795%Search for SEC Filing on Google Icon
11/7/2023CM Management LLC417,602$0.26M0.3%+11.4%13.874%Search for SEC Filing on Google Icon
8/4/2023CM Management LLC375,000$0.30M0.3%+15.4%1.821%Search for SEC Filing on Google Icon
5/8/2023CM Management LLC325,000$0.30M0.4%+3.9%1.620%Search for SEC Filing on Google Icon
2/14/2023Susquehanna International Group LLP15,211$33K0.0%N/A0.079%Search for SEC Filing on Google Icon
2/9/2023CM Management LLC312,773$0.68M0.8%+25.1%1.616%Search for SEC Filing on Google Icon
2/7/2023Lynwood Capital Management Inc.121,845$0.26M0.3%N/A0.630%Search for SEC Filing on Google Icon
11/4/2022CM Management LLC250,000$0.23M0.3%N/A1.617%Search for SEC Filing on Google Icon
8/8/2022Merit Financial Group LLC20,409$33K0.0%N/A0.132%Search for SEC Filing on Google Icon
5/5/2022National Bank of Canada FI10,000$30K0.0%+1,518.1%0.072%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Edesa Biotech logo
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Read More on Edesa Biotech

Today's Range

Now: $5.33
Low: $5.05
High: $5.74

50 Day Range

MA: $3.17
Low: $0.80
High: $7.78

52 Week Range

Now: $5.33
Low: $0.72
High: $9.37

Volume

246,675 shs

Average Volume

4,424,774 shs

Market Capitalization

$44.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Who are the company insiders with the largest holdings of Edesa Biotech?

Edesa Biotech's top insider shareholders include:
  1. Pardeep Nijhawan (CEO)
  2. Michael J Brooks (President)
  3. Der Velden Peter Van (Major Shareholder)
  4. Der Velden Peter Van (Director)
  5. Frank R Oakes (Director)
Learn More about top insider investors at Edesa Biotech.

Who are the major institutional investors of Edesa Biotech?

Edesa Biotech's top institutional shareholders include:
  1. DRW Securities LLC — 1.61%
  2. Diadema Partners LP — 0.65%
  3. State Street Corp — 0.22%
Learn More about top institutional investors of Edesa Biotech stock.

Which institutional investors are buying Edesa Biotech stock?

In the last quarter, EDSA stock was bought by institutional investors including:
  1. DRW Securities LLC
  2. Diadema Partners LP
  3. State Street Corp
During the previous year, these company insiders have bought Edesa Biotech stock:
  1. Pardeep Nijhawan (CEO)
  2. Michael J Brooks (President)
Learn More investors buying Edesa Biotech stock.

Edesa Biotech Active Insiders

Pardeep Nijhawan
Pardeep Nijhawan (Age 55)
CEO
5 recent trades
Michael J Brooks (Age 47)
President
1 recent trades